ArticleBMC psychiatry2026
Metabolic profiling in major depressive disorder with high psychological resilience: changes in amino acid and carbohydrate metabolism.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPsychological resilience varies among major depressive disorder (MDD) patients, with some exhibiting high resilience. This challenges the notion of resilience as purely protective and suggests biological heterogeneity. Both resilience and MDD have been linked to metabolic alterations, but their independent and interactive effects remain unclear. This study aims to investigate how resilience and MDD jointly affect metabolic profiles, with a focus on identifying key metabolic and pathway alterations in high-resilience MDD patients compared to healthy controls, and exploring their potential for diagnostic biomarkers.
methodsTargeted serum metabolomics using UPLC-MS/MS was conducted in MDD patients and healthy controls. Resilience was assessed via the Ego Resiliency Scale (ERS). Interaction effect analysis examined the main and interactive influences of resilience and MDD. Key metabolites in high-resilience MDD were identified by OPLS-DA and pathway enrichment. A logistic regression model with cross-validation assessed diagnostic accuracy in training and test sets.
resultsA total of 271 participants were enrolled, and about one-third of MDD patients exhibited high resilience. The MDD×resilience interaction was not significant, whereas MDD showed a significant main effect on metabolite levels. Five key metabolites were identified in high-resilience individuals, with arginine, methionine, and kynurenine downregulated and threonic and erythronic acids upregulated in the high-resilience MDD group. The diagnostic model achieved an area under the curve (AUC) of 0.811 in the test set.
conclusionsMDD status-rather than psychologically resilience-was the primary driver of serum metabolic variation. In high-resilience individuals, alterations converged on amino acid pathways (driven by lower arginine, methionine, kynurenine) and pentose-glucuronate axis (with higher threonic and erythronic acids), the latter is potentially linked to redox imbalance. These features may provide novel insights into depression-related metabolic dysregulation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.